New Smoking Cessation Treatment Research |
Post Reply |
Author | |
JFN Admin
Admin Group Joined: 11 Nov 2007 Status: Offline Points: 119 |
Post Options
Thanks(1)
Posted: 14 Aug 2012 at 00:18 |
Pfizer UK Ltd., Walton Oaks, 7th August 2012: Results of a Pfizer
commissioned study published today in Annals of Medicine reveal that
patients taking Champix (varenicline) are significantly more likely to quit
smoking and continue to abstain from smoking than those using standard dose
nicotine patch therapy (≤22mg) at all time points (4, 12, 26 and 52 weeks).
Furthermore, varenicline was associated with statistically significant
improvements at 4, 12 and 52 weeks compared to high dose nicotine patch therapy
(>22mg), and combination NRT (nicotine patch plus one additional acute
formulation of gum, lozenge, inhaler or nasal spray).
NRT is currently the mainstay of treatment for smokers in the UK, with 63% of those setting a quit date with NHS stop smoking services receiving NRT, vs. 26% of smokers who receive varenicline. Data from another review of 126,890 treatment episodes in 24 Stop Smoking Services demonstrated that nearly a third of smokers received combination NRT. The authors suggest that these new data may be used to help guide the development of guidelines and policies. Download the Press Release for Champix Study Further information about Champix can be found here
|
|
Post Reply | |
Tweet
|
Forum Jump | Forum Permissions You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum |